Man smiling behind laptop)

CSL Behring Newsroom

Recent News Releases

Heimburger Award Winners 2018
22 Jun 2018 News Release

Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.

CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology
15 Jun 2018 News Release

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients
- CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress

IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
31 May 2018 News Release

• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions
• New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients

Hemophilia Association of New Jersey Recognizes CSL CEO Paul Perreault as “Humanitarian Man of the Year”
14 May 2018 News Release

HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance

Patient Advocacy Groups Focus on Key Issues Affecting Patients
26 Apr 2018 News Release

Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
20 Apr 2018 News Release

- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM

- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms

- CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, the No.1 intravenous immunoglobulin used in hospitals is now available for CIDP patients

Want to know more about how we are sharing stories of biotech's promise?

Read Vita

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
Phone: +1 610-878-4468

Greg Healy

Product Inquiries
(Bleeding disorders and Warfarin reversal)
Phone: +1 610-878-4841

Christopher Florentz

Corporate Inquiries
Phone: +1 610-878-4316

Jennifer Purdue

Product Inquiries
(Immune disorders, Alpha-1, HAE)
Phone: +1 610-878-4802

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 6421 39-5972

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

Past News Releases by Year

News Archives 2016 pdf
News Archives 2015 pdf
News Archives 2014  pdf
News Archives 2013  pdf
News Archives 2012  pdf

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list